Life Science Development and the Future of Medicine: The Mount Sinai PerspectiveJanuary 02, 2020
Mount Sinai Innovation Partners (MSIP) participated in several conferences and events to wrap up 2019, gathering thought leaders and industry experts to discuss best practices on building a strong life science ecosystem for the purpose of helping patient populations. These events included discussions on the future of medicine and trends across the healthcare innovation space, offering an opportunity to share how the Mount Sinai Health System delivers in these areas through its technology commercialization efforts.
Erik Lium, PhD, President, MSIP, Executive Vice President and Chief Commercial Innovation Officer, Mount Sinai Health System, shared the Mount Sinai perspective with the audience and engaged in enlightening discussion with fellow panelists. Check out the events below:
NODE.Health Digital Medicine Conference
The three-day conference held from December 9-11 included a panel focused solely on Mount Sinai’s presence in the digital health space: “Mount Sinai Transformation Spotlight: Ensuring the Most Promising Technologies Advance Beyond the Bench to Make an Impact on Health.” The panel included Lium, Niyum Gandhi, Chief Population Health Officer, Mount Sinai Health System, and Barbara Murphy, MD, Professor and Chair, Icahn School of Medicine at Mount Sinai, with moderator Ashish Atreja, MD, MPH, Associate Professor, Icahn School of Medicine at Mount Sinai. Each panelist shared their insight on how digital health is evolving, from the commercialization, population health, and clinical standpoints, respectively. Both Barbara and Erik shared the success story of RenalytixAI, an AI startup listed on the London AIM stock exchange that is developing diagnostics and prognostics focusing on identifying patients who will rapidly progress towards renal failure. RenalytixAI is fueled by Mount Sinai technology, and illustrated the relevance of cutting-edge R&D that Mount Sinai innovators are applying to critical unmet healthcare needs and the effectiveness of commercialization strategies used by MSIP to ensure much-needed therapies and services are advanced to help patients.
CBInsights The Collective
Erik participated in a fireside chat at The Collective, hosted by CB Insights, on December 10, a conference gathering over 600 strategy, innovation, M&A and corporate venture capital executives to discuss driving growth at their organizations. The one-on-one interview offered a platform to share MSIP’s success in fostering an Innovation Hub within a healthcare system. Some of the strategies included creating a diverse team, developing a culture focused on outcomes, patient-centric innovation, research that leads to technologies, and effective processes to commercialize innovations.
Creating the Urban Life Science Hub of the Future
Hosted by Ennead Architects LLP, this symposium on December 10 created a community for firms seeking to raise their visibility in the science and medicine market. Over 350 developers, scientists, academic institutions, government policymakers, and investors who build, own, or invest in life science development attended. Erik participated in a panel entitled “Why is Life Science Development in Greater New York so Important for Science and Medicine?” where he shared his thoughts on technology translation including the importance of building a diverse team with corporate experience, focusing on milestone-driven research, ensuring strong relationships between academic and industry partners, creating proximity between centers of excellence and startups, and developing step-out space for expanding healthcare startups. Fellow panelists included Sam Globus, Vice President, Business Strategy and Operations of Celmatrix, Joe Landolino, Founder & CEO of Cresilon, and David McElligott, Chief Scientific Officer of Petra Pharma Corporation.
Life Sciences Summit
The Life Sciences Summit was a two-day business development conference held on November 6-7, highlighting innovation for early stage investors. The event connected emerging biotech companies and academic innovators with the capital and strategic partners they will need to move new discoveries through clinical development. Erik participated in the “IP Licensing for Emerging Companies – Successful Strategies & Recent Trends” panel, which included a discussion among fellow industry experts on how to identify valuable Intellectual Property (IP) and suitable business partners. He shared insight into how MSIP forges partnerships between academia and industry to successfully advance technologies to patients.